mOS
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
mOS
Oct 6, 2024, 16:44 |
Insight
Amrubicin + irinotecan vs cisplatin + irinotecan for SCLC
Stephen V Liu shared a post on X: "Randomized phase II: 1L amrubicin + irinotecan vs…
Oct 6, 2024, 12:22 |
Insight
Stephen V Liu: Randomized phase II trial results on amrubicin vs cisplatin for SCLC
Stephen V Liu posted the following on X: “Randomized phase II: 1L amrubicin + irinotecan…
Jun 19, 2024, 07:28 |
Insight
Naval Daver presents findings of the ENHANCE-3 study at EHA2024 - AML Hub
AML Hub shared the following post on X: . "CONGRESS EHA2024 | Naval Daver…
Jun 18, 2024, 07:07 |
Insight
Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma
Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X: "Tislelizumab plus chemotherapy vs…
Jun 16, 2024, 19:23 |
Blog
Talha Badar on Copland
Talha Badar shared a post on X: "Copland: Targeting alternating pathway in CML/CML-AP/CML-BP. 1) MDM2i…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
All:
6
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube